StreetInsider.com News Articles

Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Tue, 02 Jun 2026 08:00:00 -0400

SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio^®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 4:00 pm ET.

Webcast Link Instructions
Webcasts of the presentations can be accessed under "Events" in the investor relations section of the Belite Bio website at: https://investors.belitebio.com/presentations-events/events.

Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Tue, 02 Jun 2026 08:00:00 -0400

Belite Bio, Inc, ADR (BLTE) PT Lowered to $215 at Mizuho

Tue, 26 May 2026 05:50:22 -0400

Mizuho analyst Graig Suvannavejh lowered the price target on Belite Bio, Inc, ADR (NASDAQ: BLTE) to $215.00 (from $223.00) while maintaining a Outperform rating.

The analyst comments "BLTE reported 1Q26 results last week, with the key takeaway that all major milestones for tinlarebant remain on track. Most significantly, in our view, BLTE reaffirmed that the rolling NDA submission for tinlarebant in Stargardt disease/STGD1 (which was initiated in April) should be completed this quarter, and with key commercial leadership positions now filled, we believe that BLTE is well-positioned to execute on a product launch next year. Bigger picture, while the stock has

Belite Bio, Inc, ADR (BLTE) PT Lowered to $215 at Mizuho

Tue, 26 May 2026 05:50:22 -0400

Mizuho analyst Graig Suvannavejh lowered the price target on Belite Bio, Inc, ADR (NASDAQ: BLTE) to $215.00 (from $223.00) while maintaining a Outperform rating.

Benchmark Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE)

Fri, 22 May 2026 09:33:10 -0400

Benchmark analyst Bruce D. Jackson reiterated a Buy rating and $217.00 price target on Belite Bio, Inc, ADR (NASDAQ: BLTE).

The analyst commented, "Belite Bio hosted a 1Q business update. Upcoming events for the stock include a detailed presentation of the DRAGON Phase 3 results and the filing of an NDA with the FDA in 2Q 2026 for of tinlarebant in Stargardt disease (STGD1). We’re also looking forward to an interim read from the PHOENIX trial of tinlarebant In Geographic Atrophy (GA), the most severe form of Dry AMD, during 2H 2026. Belite ended the quarter with $276 million in cash

H.C. Wainwright Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE)

Thu, 21 May 2026 06:38:56 -0400

H.C. Wainwright analyst Yi Chen reiterated a Buy rating and $200.00 price target on Belite Bio, Inc, ADR (NASDAQ: BLTE).

The analyst commented: "Yesterday, Belite Bio reported its 1Q26 financial results. Net loss was $26.9M, or ($0.68) per share, less than our estimated loss of $27.5M. Of note, the company initiated a rolling submission of New Drug Application (NDA) to the U.S. FDA for tinlarebant as a novel oral therapy for the treatment of Stargardt disease type 1 (STGD1) in April 2026. Management expects to complete the NDA submission in the current quarter. Tinlarebant has been granted Breakthrough Therapy, Fast Track,

Form 6-K BELITE BIO, INC For: May 20

Wed, 20 May 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260520/26524310.html

Form 6-K BELITE BIO, INC For: May 20

Wed, 20 May 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260520/26524310.html

Belite Bio (BLTE) Tops Q1 EPS by 30c

Wed, 20 May 2026 06:03:35 -0400

Belite Bio (NASDAQ: BLTE) reported Q1 EPS of ($0.34), $0.30 better than the analyst estimate of ($0.64).

For earnings history and earnings-related data on Belite Bio (BLTE) click here.

Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update

Wed, 20 May 2026 06:00:00 -0400

Initiated a rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tinlarebant for the treatment of Stargardt disease type 1 (STGD1); submission expected to be completed in the second quarter of 2026
Commercialization preparation for STGD1 underway; hiring of all key commercial leadership positions completed
Cash and cash equivalents, U.S. treasury bills and notes: $798.6 million as of March 31, 2026
Conference call and webcast on Wednesday, May 20, 2026, at 4:30 p.m. ET